テラプレビル (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "テラプレビル" in Japanese language version.

refsWebsite

Global rank Japanese rank

8doi.org

2^nd place

6^th place

7nih.gov

4^th place

24^th place

2pmda.go.jp

6,690^th place

394^th place

2mt-pharma.co.jp

low place

4,584^th place

2nejm.org

2,374^th place

2,486^th place

1prous.com

low place

1medscape.com

719^th place

3,311^th place

1boston.com

310^th place

1,275^th place

boston.com

Staff, Boston.com. December 19, 2012. Vertex updates label of hepatitis C drug after reports of a ‘small number of fatal skin reactions’

doi.org

Kim, Jenny; Culley, Colleen; Mohammad Rima, Telaprevir (2012). “An Oral Protease Inhibitor for Hepatitis C Virus Infection”. Am J Health Syst Pharm 69 (1): 19–33. doi:10.2146/ajhp110123.
Kiser JJ, Burton JR, Anderson PL, Everson GT (May 2012). “Review and Management of Drug Interactions with Boceprevir and Telaprevir”. Hepatology 55 (5): 1620–8. doi:10.1002/hep.25653. PMC 3345276. PMID 22331658.
Revill, P., Serradell, N., Bolos, J., Rosa, E. (2007). “Telaprevir”. Drugs of the Future 32 (9): 788. doi:10.1358/dof.2007.032.09.1138229.
Lin C, Kwong AD, Perni RB (March 2006). “Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease”. Infect Disord Drug Targets 6 (1): 3–16. doi:10.2174/187152606776056706. PMID 16787300.
McHutchison JG, Manns MP, Muir AJ, et al. (2010). “Telaprevir for previously treated chronic HCV infection”. N Engl J Med 362 (14): 1292–303. doi:10.1056/NEJMoa0908014. PMID 20375406.
Zeuzem S, Andreone P, Pol S, et al. (2011). “Telaprevir for retreatment of HCV infection.”. N Engl J Med 364 (25): 2417–28. doi:10.1056/NEJMoa1013086. PMID 21696308.
Jacobson IM, McHutchison JG, Dusheiko G, et al. (2011). “Telaprevir for previously untreated chronic hepatitis C virus infection.”. N Engl J Med 364 (25): 2405–16. doi:10.1056/NEJMoa1012912. PMID 21696307.
Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. (2011). “Response-guided telaprevir combination treatment for hepatitis C virus infection.”. N Engl J Med 365 (11): 1014–1024. doi:10.1056/NEJMoa1014463. PMID 21916639.

medscape.com

“FDA Approves Telaprevir for HCV” (2011年5月23日). 2015年3月3日閲覧。

mt-pharma.co.jp

“新しい作用機序を有するC型慢性肝炎治療薬抗ウイルス剤「テラビック錠250mg」の国内における製造販売承認取得について”. 田辺三菱製薬 (2011年9月26日). 2015年3月3日閲覧。
“抗ウイルス剤「テラビック錠250mg」ジェノタイプ2型C型慢性肝炎に係る追加適応の承認取得のお知らせ”. 田辺三菱製薬 (2014年9月14日). 2015年3月3日閲覧。

nejm.org

content.nejm.org

McHutchison JG, Manns MP, Muir AJ, et al. (2010). “Telaprevir for previously treated chronic HCV infection”. N Engl J Med 362 (14): 1292–303. doi:10.1056/NEJMoa0908014. PMID 20375406.

nejm.org

Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. (2011). “Response-guided telaprevir combination treatment for hepatitis C virus infection.”. N Engl J Med 365 (11): 1014–1024. doi:10.1056/NEJMoa1014463. PMID 21916639.

nih.gov

pubmed.ncbi.nlm.nih.gov

Kiser JJ, Burton JR, Anderson PL, Everson GT (May 2012). “Review and Management of Drug Interactions with Boceprevir and Telaprevir”. Hepatology 55 (5): 1620–8. doi:10.1002/hep.25653. PMC 3345276. PMID 22331658.
Lin C, Kwong AD, Perni RB (March 2006). “Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease”. Infect Disord Drug Targets 6 (1): 3–16. doi:10.2174/187152606776056706. PMID 16787300.
McHutchison JG, Manns MP, Muir AJ, et al. (2010). “Telaprevir for previously treated chronic HCV infection”. N Engl J Med 362 (14): 1292–303. doi:10.1056/NEJMoa0908014. PMID 20375406.
Zeuzem S, Andreone P, Pol S, et al. (2011). “Telaprevir for retreatment of HCV infection.”. N Engl J Med 364 (25): 2417–28. doi:10.1056/NEJMoa1013086. PMID 21696308.
Jacobson IM, McHutchison JG, Dusheiko G, et al. (2011). “Telaprevir for previously untreated chronic hepatitis C virus infection.”. N Engl J Med 364 (25): 2405–16. doi:10.1056/NEJMoa1012912. PMID 21696307.
Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. (2011). “Response-guided telaprevir combination treatment for hepatitis C virus infection.”. N Engl J Med 365 (11): 1014–1024. doi:10.1056/NEJMoa1014463. PMID 21916639.

ncbi.nlm.nih.gov

Kiser JJ, Burton JR, Anderson PL, Everson GT (May 2012). “Review and Management of Drug Interactions with Boceprevir and Telaprevir”. Hepatology 55 (5): 1620–8. doi:10.1002/hep.25653. PMC 3345276. PMID 22331658.

pmda.go.jp

info.pmda.go.jp

“テラビック錠250mg 添付文書” (2016年5月). 2016年6月27日閲覧。
“テラビック錠250mg インタビューフォーム” (PDF) (2014年9月). 2015年3月3日閲覧。

prous.com

journals.prous.com

Revill, P., Serradell, N., Bolos, J., Rosa, E. (2007). “Telaprevir”. Drugs of the Future 32 (9): 788. doi:10.1358/dof.2007.032.09.1138229.